Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
Hideaki Katagiri,1 Masanori Taketsuna,2 Shinpei Kondo,3 Kenta Kajimoto,4 Etsuko Aoi,5 Yuka Tanji1 1Bio Medicine, 2Statistical Sciences, 3Post Marketing Study Management, 4Scientific Communications, Medicines Development Unit Japan, 5Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1f759ce9f6f440dd9576b46920cb5df4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1f759ce9f6f440dd9576b46920cb5df4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1f759ce9f6f440dd9576b46920cb5df42021-12-02T05:53:58ZSafety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study1178-2021https://doaj.org/article/1f759ce9f6f440dd9576b46920cb5df42018-01-01T00:00:00Zhttps://www.dovepress.com/safety-and-effectiveness-of-rapid-acting-intramuscular-olanzapine-for--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Hideaki Katagiri,1 Masanori Taketsuna,2 Shinpei Kondo,3 Kenta Kajimoto,4 Etsuko Aoi,5 Yuka Tanji1 1Bio Medicine, 2Statistical Sciences, 3Post Marketing Study Management, 4Scientific Communications, Medicines Development Unit Japan, 5Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly Japan K.K., Kobe, Japan Objective: The objective of this study was to evaluate the safety and effectiveness of rapid-acting intramuscular (IM) olanzapine in the treatment of acute agitation associated with schizophrenia in real-world clinical settings in Japan.Methods: In this multicenter, postmarketing surveillance (PMS) study, patients with acute agitation associated with schizophrenia were treated with IM olanzapine daily in a daily clinical setting. The observational period ranged from 1 to 7 days, including the day of initial administration. Safety was assessed by reporting treatment-emergent adverse events (TEAEs) and adverse drug reactions (ADRs). The Positive and Negative Syndrome Scale – Excited Component (PANSS-EC) score was used to evaluate effectiveness at baseline and at 2 hours (after each administration), 2 days, and 3 days (end of the observational period) from the last administration of the IM olanzapine injection.Results: The safety analysis set included 999 patients, and the initial dose of 10 mg was administered to 955 patients. TEAEs were reported in 28 patients (36 events), the most common of which were dyslalia (5 patients), akathisia and somno­lence (4 patients each), hepatic function abnormal (3 patients), and constipation and dehydration (2 patients each). One serious adverse event of akathisia occurred during the observation period. The PANSS-EC score (mean ± standard deviation) was 23.3±6.4 (n=625) at baseline, 16.9±7.0 (n=522) at 2 hours after initial injection, and 14.9±6.5 (n=650) at the last observation carried forward.Conclusion: The results of this Japanese PMS study demonstrated that IM olanzapine is safe and has a favorable effectiveness profile in the treatment of schizophrenia patients with acute agitation. Keywords: agitation, Japanese, postmarketing surveillance study, rapid-acting intramuscular olanzapine, schizophrenia, PANSS-ECKatagiri HTaketsuna MKondo SKajimoto KAoi ETanji YDove Medical PressarticleAgitationJapanesePostmarketing Surveillance StudyRapid-Acting Intramuscular OlanzapineSchizophreniaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 265-272 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Agitation Japanese Postmarketing Surveillance Study Rapid-Acting Intramuscular Olanzapine Schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Agitation Japanese Postmarketing Surveillance Study Rapid-Acting Intramuscular Olanzapine Schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Katagiri H Taketsuna M Kondo S Kajimoto K Aoi E Tanji Y Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study |
| description |
Hideaki Katagiri,1 Masanori Taketsuna,2 Shinpei Kondo,3 Kenta Kajimoto,4 Etsuko Aoi,5 Yuka Tanji1 1Bio Medicine, 2Statistical Sciences, 3Post Marketing Study Management, 4Scientific Communications, Medicines Development Unit Japan, 5Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly Japan K.K., Kobe, Japan Objective: The objective of this study was to evaluate the safety and effectiveness of rapid-acting intramuscular (IM) olanzapine in the treatment of acute agitation associated with schizophrenia in real-world clinical settings in Japan.Methods: In this multicenter, postmarketing surveillance (PMS) study, patients with acute agitation associated with schizophrenia were treated with IM olanzapine daily in a daily clinical setting. The observational period ranged from 1 to 7 days, including the day of initial administration. Safety was assessed by reporting treatment-emergent adverse events (TEAEs) and adverse drug reactions (ADRs). The Positive and Negative Syndrome Scale – Excited Component (PANSS-EC) score was used to evaluate effectiveness at baseline and at 2 hours (after each administration), 2 days, and 3 days (end of the observational period) from the last administration of the IM olanzapine injection.Results: The safety analysis set included 999 patients, and the initial dose of 10 mg was administered to 955 patients. TEAEs were reported in 28 patients (36 events), the most common of which were dyslalia (5 patients), akathisia and somno­lence (4 patients each), hepatic function abnormal (3 patients), and constipation and dehydration (2 patients each). One serious adverse event of akathisia occurred during the observation period. The PANSS-EC score (mean ± standard deviation) was 23.3±6.4 (n=625) at baseline, 16.9±7.0 (n=522) at 2 hours after initial injection, and 14.9±6.5 (n=650) at the last observation carried forward.Conclusion: The results of this Japanese PMS study demonstrated that IM olanzapine is safe and has a favorable effectiveness profile in the treatment of schizophrenia patients with acute agitation. Keywords: agitation, Japanese, postmarketing surveillance study, rapid-acting intramuscular olanzapine, schizophrenia, PANSS-EC |
| format |
article |
| author |
Katagiri H Taketsuna M Kondo S Kajimoto K Aoi E Tanji Y |
| author_facet |
Katagiri H Taketsuna M Kondo S Kajimoto K Aoi E Tanji Y |
| author_sort |
Katagiri H |
| title |
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study |
| title_short |
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study |
| title_full |
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study |
| title_fullStr |
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study |
| title_full_unstemmed |
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study |
| title_sort |
safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – japan postmarketing surveillance study |
| publisher |
Dove Medical Press |
| publishDate |
2018 |
| url |
https://doaj.org/article/1f759ce9f6f440dd9576b46920cb5df4 |
| work_keys_str_mv |
AT katagirih safetyandeffectivenessofrapidactingintramuscularolanzapineforagitationassociatedwithschizophreniandashjapanpostmarketingsurveillancestudy AT taketsunam safetyandeffectivenessofrapidactingintramuscularolanzapineforagitationassociatedwithschizophreniandashjapanpostmarketingsurveillancestudy AT kondos safetyandeffectivenessofrapidactingintramuscularolanzapineforagitationassociatedwithschizophreniandashjapanpostmarketingsurveillancestudy AT kajimotok safetyandeffectivenessofrapidactingintramuscularolanzapineforagitationassociatedwithschizophreniandashjapanpostmarketingsurveillancestudy AT aoie safetyandeffectivenessofrapidactingintramuscularolanzapineforagitationassociatedwithschizophreniandashjapanpostmarketingsurveillancestudy AT tanjiy safetyandeffectivenessofrapidactingintramuscularolanzapineforagitationassociatedwithschizophreniandashjapanpostmarketingsurveillancestudy |
| _version_ |
1718400157599399936 |